Pharma Industry

Executive Director
Miss. Manisha S Taur

FOUNDER - ANURADHA GROUPS

                         India is the largest provider of generic drugs globally. Indian pharmaceutical sector supplies over 50% of global demand for various vaccines, 40% of generic demand in the US and 25% of all medicine in the UK. Globally, India ranks 3rd in terms of pharmaceutical production by volume and 14th by value. The domestic pharmaceutical industry includes a network of 3,000 drug companies and 10,500 manufacturing units.
The pharmaceutical industry in India, US$40 billion by value, world’s 3rd largest by overall volume and world’s largest as provider of generic medicines globally, with 20% and 3.5% share of total global pharmaceutical exports by volume and value respectively to more than 200 countries and territories in 2021.

                        With industry standards compliant mega production capabilities and large number of skilled dometic workforce, Indian exports meet the standards and requirements of highly regulated markets of USA, UK, European Union and Canada. According to the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, domestic pharmaceutical market turnover reached Rs 129,015 crore (US$18.12 billion) in 2018, growing 9.4 per cent year-on-year and exports revenue was US$17.28 billion in FY18 and US$19.14 billion in FY19.

                    As of 2021, most of pharmaceuticals made in India are low cost generic drug which comprise most of pharmaceutical export of India. Patented medicine are imported. APIs are imported from China (66% supplies by volume worth US$2.4 billion) and Germany (US$1.6 billion) as well as from US, Italy and Singapore.To foster an Atmanirbhar Bharat by enhancing the R&D, Make in India product development and high-value production capabilities, import substitution and domestic manufacture of active pharmaceutical ingredient (API) the government has introduced a US$2 billion incentive program which will run from 2021-22 to 2027-28. In 2019 the Department of Pharmaceuticals announced that as part of the Make in Indiainitiative, drugs for local use and exports must have 75% and 10% local APIs respectively and a bill of material must be produced for verification.

                  3 PORT ICC  encourage the growth of pharma  manufacturing by Indian companies.